Role of carrier ligand in platinum resistance in L1210 cells
- PMID: 2208108
Role of carrier ligand in platinum resistance in L1210 cells
Abstract
We have examined the effect of carrier ligands on platinum accumulation, incorporation of platinum into DNA, cytotoxicity of Pt-DNA adducts, and repair of Pt-DNA adducts in three L1210 cell lines: L1210/0, which is sensitive to most types of platinum compounds; L1210/DDP, which is resistant to platinum compounds with the ethylenediamine (en) carrier ligand but sensitive to those with the diaminocyclohexane (dach) ligand; and L1210/DACH, which is resistant to dach-Pt compounds but sensitive to en-Pt compounds. There was a selective decrease in accumulation of dach-Pt in the L1210/DACH line and of en-Pt in the L1210/DDP line. Intracellular dach-Pt was incorporated into DNA to a lesser extent than en-Pt in both resistant cell lines. Cytotoxicity of en-Pt adducts was less than that of dach-Pt adducts in the L1210/DDP line, while the reverse was true in the L1210/DACH line. Increased repair was seen in both resistant cell lines; a carrier ligand effect was seen only in the L1210/DDP line, which showed a greater initial rate of repair for en-Pt than dach-Pt adducts. These data suggest that carrier ligand effects seen in resistant cell lines may be due, in part, to differences in accumulation of platinum, repair of Pt-DNA adducts, and tolerance of Pt-DNA adducts.
Similar articles
-
Role of carrier ligand in platinum resistance of human carcinoma cell lines.Cancer Res. 1993 Feb 15;53(4):799-805. Cancer Res. 1993. PMID: 8428361
-
Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.Cancer Res. 1993 Oct 1;53(19):4567-72. Cancer Res. 1993. PMID: 8402629
-
Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.Carcinogenesis. 1991 Dec;12(12):2253-7. doi: 10.1093/carcin/12.12.2253. Carcinogenesis. 1991. PMID: 1747924
-
Oxaliplatin: mechanism of action and antineoplastic activity.Semin Oncol. 1998 Apr;25(2 Suppl 5):4-12. Semin Oncol. 1998. PMID: 9609103 Review.
-
Cellular and molecular aspects of drugs of the future: oxaliplatin.Cell Mol Life Sci. 2002 Nov;59(11):1914-27. doi: 10.1007/pl00012514. Cell Mol Life Sci. 2002. PMID: 12530522 Free PMC article. Review.
Cited by
-
Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance.Ecancermedicalscience. 2009;3:153. doi: 10.3332/ecancer.2009.153. Epub 2009 Sep 24. Ecancermedicalscience. 2009. PMID: 22276017 Free PMC article.
-
Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.Jpn J Cancer Res. 2000 Dec;91(12):1326-32. doi: 10.1111/j.1349-7006.2000.tb00921.x. Jpn J Cancer Res. 2000. PMID: 11123433 Free PMC article.
-
An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells.Mol Cell Biol. 1995 Jan;15(1):290-7. doi: 10.1128/MCB.15.1.290. Mol Cell Biol. 1995. PMID: 7799936 Free PMC article.
-
Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II).Br J Cancer. 1996 Aug;74(4):590-6. doi: 10.1038/bjc.1996.406. Br J Cancer. 1996. PMID: 8761375 Free PMC article.
-
An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts.Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10772-6. doi: 10.1073/pnas.89.22.10772. Proc Natl Acad Sci U S A. 1992. PMID: 1438274 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials